Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...

Merck said early Monday that a new cholesterol-lowering pill worked well in two late-stage trials, boosting the stock in ...

Merck, which is evaluating the safety and efficacy of enlicitide for the treatment of adults with hyperlipidemia on lipid-lowering therapies, including at least a statin, said the Phase 3 studies met ...

Enlicitide, which could be the first oral medication that blocks the protein PCSK9, helped cut cholesterol levels in a pair ...

Merck & Co.’s ambition to get the first oral PCSK9 inhibitor to market came one step closer this morning as the pharma ...

Shares of NewAmsterdam Pharma rose in premarket trading Monday after finding positive benefits for treating Alzheimer's Disease in its cholesterol drug study. Shares traded 9.2% higher ahead of the ...

The average woman's weight can vary depending on age, physical traits, certain health conditions, metabolism, appetite, and ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...

(Reuters) -Merck said on Monday its drug met the main goal of reducing a type of cholesterol in two late-stage studies.

Pre-specified analyses show that obicetrapib treatment leads to statistically significant and clinically meaningful reductions in the primary outcome measure of Alzheimer's disease biomarker in both ...